Status: Recruiting
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Participants needed: 450
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: UroGen Pharma Ltd.Updated: Sep 29, 2026Locations: 22Duration: 3 Years
Eligibility criteria
Adults >18 years old and capable of giving informed consent. [+2]
Incapable of giving informed consent (e.g., incarcerated individuals, individual... [+4]